Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00990067
Other study ID # EKBB 253/09
Secondary ID
Status Completed
Phase Phase 1
First received October 5, 2009
Last updated January 24, 2013
Start date November 2009
Est. completion date May 2010

Study information

Verified date January 2013
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determinate the effect of a pre-treatment with the combined serotonin (5-HT) and norepinephrine (NE) transport blocker duloxetine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The investigators hypothesize that duloxetine will attenuate the subjective and cardiovascular response to MDMA.


Description:

3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is widely used by young people for its euphoric effects. MDMA releases serotonin (5-HT), norepinephrine (NE), and dopamine through an interaction with the corresponding presynaptic monoamine uptake transporter. 5-HT transport inhibitors block MDMA-induced 5-HT release in vitro or in animals and also attenuate the subjective and cardiovascular response to MDMA in humans. NE transport inhibitors similarly prevent the MDMA-induced release of NE in cell assays and attenuate behavioral effects of MDMA in animals. Effects of the NE transporter inhibitor reboxetine on the response to MDMA in humans are currently investigated. Here we suggest evaluating effects of pretreatment with the combined 5-HT and NE transport blocker duloxetine on the pharmacodynamics and pharmacokinetics of MDMA. The study will use a randomized double-blind cross-over design with four experimental sessions. Duloxetine (120 mg) or placebo will be administered 16 h and 4 h before the administration of MDMA (125 mg) or placebo to 16 healthy volunteers. Subjective and cardiovascular responses and plasma samples for pharmacokinetics will be repeatedly assessed throughout the experiments.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Sufficient understanding of the German language

- Subjects understand the procedures and the risks associated with the study

- Participants must be willing to adhere to the protocol and sign the consent form

- Participants must be willing to refrain from taking illicit psychoactive substances during the study.

- Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session. Subjects must agree not to smoke tobacco for 1 h before and 4 hours after MDMA administration.

- Participants must be willing not to drive a traffic vehicle in the evening of the study day.

- Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session.

- Body mass index: 18-25 kg/m2

Exclusion Criteria:

- Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (>140/90 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder.

- Current or previous psychotic or affective disorder

- Psychotic or affective disorder in first-degree relatives

- Prior illicit drug use (except THC (Tetrahydrocannabinol)-containing products) more than 5 times or any time within the previous 2 months.

- Pregnant or nursing women.

- Participation in another clinical trial (currently or within the last 30 days)

- Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.)

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Intervention

Drug:
3,4-Methylenedioxymethamphetamine
125 mg, single dose
Duloxetine
120 mg two doses 12h and 2h before MDMA
Placebo
capsules identical to MDMA or duloxetine

Locations

Country Name City State
Switzerland Clinical Pharmacology & Toxicology, University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Genetic polymorphisms Effects of genetic polymorphisms on the response to MDMA assessed after study completion No
Primary Effect of duloxetine on the subjective response to MDMA 24h No
Secondary Effect of duloxetine on cardiovascular effects of MDMA 6h No
Secondary Effect of duloxetine on pharmacokinetics of MDMA 6h No
Secondary Effect of MDMA on duloxetine pharmacokinetics 6h No
Secondary Tolerability of MDMA and duloxetine 7 days No
Secondary Effect of duloxetine on neuroendocrine responses to MDMA 6h No
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Recruiting NCT04157062 - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Enrolling by invitation NCT06084221 - Fatal Overdose Review Teams - Research to Enhance Surveillance Systems N/A
Completed NCT02907944 - Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation N/A
Completed NCT02570360 - Exercise and Treatment-as-usual in Substance Use Treatment Outcomes N/A
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT02125539 - Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment Phase 2
Completed NCT02715557 - Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers N/A
Completed NCT02388243 - The Computer-based Drug and Alcohol Training Assessment in Kenya N/A
Completed NCT01633138 - Performance-based Reinforcement to Enhance Cognitive Remediation Therapy N/A
Completed NCT02218970 - The Effect of Muscular Strength Training in Patients With Drug Addiction N/A
Completed NCT01591239 - Home-Based Program to Help Parents of Drug Abusing Adolescents N/A
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Withdrawn NCT01224002 - A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine N/A
Withdrawn NCT00891631 - Primary Care iSBIRT to Reduce Serious Teen Health Risks Phase 1/Phase 2
Completed NCT01365247 - Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD) N/A
Completed NCT00970372 - Dual-Diagnosis and Compulsory Treatment N/A
Completed NCT00419029 - Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment N/A